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1  | INTRODUC TION
Sampling a person's blood is a common and frequently used clinical 
diagnostic procedure (Thakker et al., 2015). Blood sampling through 
direct venepuncture is an invasive procedure that is associated with 
patient discomfort and decreased satisfaction (Buowari, 2013). It is 
possible to reduce patent discomfort by drawing blood through an 
existing peripheral intravenous cannula (PIVC) and replacing PIVCs 
only when clinically indicated (Rickard et al., 2012). However, there 
is limited consensus across Australian jurisdictions as to whether 
(and why) the practice of drawing blood through PIVC should be sup-
ported. This paper will look at sources of evidence used to inform 
the creation of government health policy using the specific example 
of Australian state government policies on the use of PIVC for blood 
drawing.
2  | BACKGROUND
In academia, the word evidence is used to refer to information that 
supports or disproves an hypothesis and is produced and validated 
through the use of specific protocols and measures (Cairney, 2016). 
Evidence can be taken from a variety of sources and be presented in a 
variety of forms, each of which will have an impact on the evidence's 
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Abstract
Aim: To examine the quality of evidence used to inform health policies. Policies on 
peripheral intravenous cannulas were used as exemplars.
Design: An organizational case study design was used, using the STROBE reporting 
guidelines.
Methods: Policy guidelines were sourced between June and September 2018 from 
health departments in Australia. Seven documents were compared regarding intrave-
nous cannula dwell times and blood collection use. Evidence used in the documents 
was critiqued using assessment guideline from the Oxford Centre for Evidence Based 
Medicine.
Results: Large variations exist between policies regarding blood sampling and dwell 
time. Evidence used a variety of sources. Few references received an A evidence rat-
ing and policies differed in their interpretation of evidence.
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credibility (International Council of Nursing, 2012). Academic evi-
dence is generally ranked according to validity of results on a scale 
from systematic reviews of randomized control trials as the best 
evidence, through to personal opinion and commentary as the least 
reliable evidence (Cairney, 2016). It is possible to have significant di-
vergent opinions when deciding whether evidence exists, is relevant 
and should be applied to specific situations or included in public policy 
(Newman, Cherney, & Head, 2017).
Clinical healthcare workers often seek to incorporate evidence 
into health care through the use of evidence-based practice (EBP). 
The term EBP is associated with the work of Archie Cochrane and his 
belief that clinicians should use only the most effective and proven 
healthcare procedures available (Mackey & Bassendowski, 2017). In 
clinical situations, EBP incorporates the best available evidence with 
the needs of health service users and the clinical skills of healthcare 
staff (ICN, 2012).
There can be significant delays times between the discovery of 
quality evidence and implementation of that evidence into clinical 
practice (Melnyk, Lynn, English, & Ellen, 2014). The biggest dif-
ficulty with EBP may not be creating the evidence but translating 
the evidence and ensuring that clinical practice is changed in favour 
of the evidence (ICN, 2012). Healthcare organizations may lack 
EBP when they are unaware of evidence-based research or when 
research is not translated into policy (Stavor, Zedreck-Gonzalez, & 
Hoffmann, 2017). Implementing EBP is a collective and corporate re-
sponsibility, as individual practitioners work within broader environ-
ments of teams and organizational requirements (Williams, Perillo, 
& Brown, 2015). It should also be acknowledged that patient care 
decisions are rarely made on the basis of academic and scientific ev-
idence alone but are required to incorporate individual patient and 
staff factors, judgements and values (ICN, 2012).
Having healthcare policies and guidelines that are informed by 
current best evidence are of importance to ensure high-quality and 
safe patient care. Yet there are several notable practices that con-
tinue in Australian health care in the face of high-quality evidence. 
Examples include changing peripheral intravenous cannulas rou-
tinely rather than when clinically indicated and routine oxygenation 
of patients (Melnyk, 2017; Rickard et al., 2012).
In Australia, state governments are responsible for the operation 
healthcare service delivery and the creation of health policy within 
their jurisdictions (Dixit & Sambasivan, 2018).
It is often unclear how the concept of EBP is understood at a gov-
ernment policy level, as the use of evidence in policies is not always 
clearly referenced or identified. It is commonly alleged that policy-
makers are either ignorant of evidence related to their policy field or 
choose to ignore and fail to act on known evidence (Cairney, 2016). 
However, there is a specific and specialized skill set associated with 
evaluating large volumes of evidence and then using the results 
to produce recommendations (ICN, 2012). Newman et al. (2017) 
have argued that structural limitations within the Australian public 
service may have left governments unprepared to engage with re-
search-based and academic evidence.
Peripheral intravenous cannula (PIVC) is medical devices that are 
inserted into and remain in a person's peripheral vein to allow contin-
ued venous access (Wong, Cooper, Brown, Boyd, & Levinson, 2018). 
It is estimated that up to 80% of hospitalized patients will require in-
travenous therapy at some point during their inpatient hospital stay 
(Yagnik, Graves, & Thong, 2017). Peripheral intravenous cannula is 
the most commonly inserted vascular access device and can be used 
for administration of medications, blood sampling and management 
of conditions (Carr et al., 2016). Health professionals understand the 
importance of obtaining accurate blood sampling; however, there 
is considerable variability in the methods used (Bentley, Thakore, 
Muir, Baird, & Lee, 2016). Traditionally, most blood samples have 
been drawn from peripheral venepuncture, although increasingly 
PIVCs are being used for blood sampling (Carr et al., 2016; Davies, 
Coventry, Jacob, Stoneman, & Jacob, 2019).
While blood can be drawn from PIVC, there are several states 
and territories in Australia where this is avoided, in part, due to the 
perceived association between PIVC blood draws and increased 
risk of haemolysis, sample dilution, bloodstream infection and 
phlebitis (Mulloy, Lee, Gregas, Hoffman, & Ashley, 2018). Yet the 
evidence around the use of PIVC for blood sampling is unclear. A 
systematic review by Jeong et al. (2019) found that sampling from 
PIVC or venepuncture is likely to provide equivalent levels of ac-
curacy for the most commonly used tests. This is in line with a 
systematic review by Coventry and colleagues (2019) that found 
limited evidence to suggest that use of PIVC for blood sampling 
contributed to decreased accuracy, but that PIVC use may lead 
to increased haemolysis rates. Relying on policies that are made 
based on poorly informed evidence is one of the main contribu-
tors to healthcare service failures (ICN, 2012). There are variances 
in practice regarding obtaining blood samples from PIVC postin-
sertion between individual nurses, health services and states in 
Australia (Davies et al., 2019). These variations and the evidence 
used to support them are the focus of this study. Therefore, the 
aim of this study is to examine what evidence is used to support 
Australian State government guidelines on peripheral intravenous 
cannula use?
3  | METHODS
This research was conducted as an organizational case study, fol-
lowing the Strengthening the Reporting of Observational Studies in 
Epidemiology reporting guidelines (See File S1). Ethics approval was 
not required for this study. The authors did not have any conflict of 
interest to declare, and there was no funding for this project.
In June 2018, policy guidelines relating to PIVC use were sought 
from the relevant health departments from all Australian States and 
Territories. In most cases, the policies were freely available online 
from the health-department websites. Where policies were not 
readily available, the health department in question was contacted 
directly and the policies were provided via email.
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Seven Australian states/territories were included in the compar-
ison. The jurisdictions were Australian Capital Territory (ACT), New 
South Wales (NSW), Northern Territory (NT), Queensland (QLD), 
Tasmania (Tas), Victoria (Vic) and Western Australia (WA). During 
data collection, it was found that South Australia (SA) did not have 
an overarching policy for the use of PIVC, but that polices were set 
by several local health networks. Due to the inability to access sev-
eral the local health network policies, it was decided to exclude SA 
from this study.
The policies were assessed according to firstly, how well the pol-
icy covered the procedure of PIVC blood draws and secondly, PIVC 
dwell time. Data were extracted from the documents including the 
year the policy was published, the title of the document and whether 
the policy included reference to the practice of sampling of blood 
from a PIVC. Also extracted were details of whether blood could 
be drawn from a PIVC on insertion, could blood be routinely drawn 
from a PIVC, could a PIVC be inserted for the purpose of blood col-
lection, was there a procedure on how to draw blood from a PIVC, 
were there any exceptions and did the policy outline when a PIVC 
should be removed or replaced.
The evidence and type of evidence that was used to support 
these guidelines were also extracted. To determine the type of ev-
idence being used to justify positions taken in the guidelines, the 
reference lists and bibliographies of the guidelines were analysed. 
Data were collected relating to evidence type, where the evidence 
was taken from, who created the evidence and how recently it was 
published.
Using assessment guidelines set out by the Oxford Centre for 
Evidence Based Medicine (OCEBM) (2009), the choices of evidence 
used by the guidelines were assessed for quality. The OCEBM guide-
lines provide a way to categorize evidence into levels, allowing evi-
dence in each level to be assigned a numerical value and a grade to 
be provided for a reference list based on the proportion or number 
of higher scoring items. Items are scored from 1 (Systematic Reviews 
of Randomized Control Trials) through to 5 (expert opinion), the 
number of sources from each category is identified, and a grade from 
A–D is applied. Allocation of an A grade indicates a strong level of 
evidence, while D grade indicates a weak level of evidence. The pol-
icies were also compared, to highlight possible cross-jurisdictional 
inconsistencies. The grades of evidence were compared with the 
content of the policies to assess whether there were consistent rec-
ommendations found in guidelines that contained high levels of evi-
dence. Two researchers independently analysed the data extracted 
from the policy documents. Where disagreements occurred, these 
were brought to the research team and discussed until consensus 
was reached.
4  | FINDINGS
Data extracted from the policy documents identified large variations 
between policy documents in the information provided. Table 1 lists 
the information covered by the policies. Policies were all published 
between 2012–2017. Six of the documents directly referred to blood 
sampling from PIVCs, with three documents allowing routine col-
lection of blood through a PIVC and three documents prohibiting 
collection of blood through a PIVC. Procedures for drawing blood 
through a PIVC differed, from specifying flushing techniques, stating 
only large veins to be used and whether a vacutainer could be used 
for withdrawal. One policy provided conflicting information, sug-
gesting PIVCs could be used for routine blood collection and stating 
that blood may only be collected from PIVCs if it was specifically 
inserted for that reason (Tas, 2016). Some policies provided strict 
rules in relation to the use of PIVC for blood draws and set out spe-
cific exceptional circumstances as the only times at which they could 
be used (WA, 2017; QLD, 2015). The guidelines were similar in their 
approach to PIVC dwell time. Most Australian jurisdictions require 
PIVC to be replaced at 72 hr, with only Queensland allowing replace-
ment to occur as clinically indicated.
The type of evidence used by the different documents also 
varied (Table 2. Type of evidence used). Policies were examined to 
assess currency and the frequencies at which they were reviewed. 
Documents had publication dates between 2012–2017, all were cur-
rent within the date stated for review, although one state did not list 
a review date. All policy documents had references cited but differed 
as to whether the references were cited in text, at the end of the 
chapter only, or in a reference list at the end of the document. The 
evidence used for policy development was taken from a wide variety 
of different sources including recent and dated academic journals, 
legislation/government policies, manufacturer guidelines and grey 
literature. Some of the state guidelines included citations for the rel-
evant guidelines in other Australian jurisdictions, creating a circle of 
“self-citing.”
The level of evidence provided in each document was mapped 
against the OCEBM Levels of Evidence (Table 3). Identified varia-
tions in evidence are graded from categories A-D. New South Wales 
and QLD both score A for their OCEBM evidence use, however, 
comparing the content of their policies from table 1, show significant 
discrepancies. These discrepancies are most apparent in the applica-
tion of evidence to cannula dwell time, with QLD allowing changes 
to occur when clinically indicated, as opposed to NSW where they 
are required to be changed every 72 hr (Table 1). It is also notewor-
thy that the guidelines in Vic do not seem to be based on any form of 
evidence and received an evidence grade of D.
5  | DISCUSSION
Understanding the way that state governments view the evidence that 
they use when creating clinical guidelines can provide significant insight 
for those working in evidence creation. This study has found that many 
Australian state governments have endorsed policies relating to the use 
of peripheral intravenous cannula, including blood sampling and dwell 
time that are lacking, or informed to a large degree by, non-academic 
evidence. The use of peripheral intravenous cannula and evidence used 
to support guidelines positions is inconsistent and lacks clarity.
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It is intuitively known that when health policies are informed 
by robust and tested evidence, those policies are likely to result 
in more equitable and sustainable gains to population health (van 
de Goor et al., 2017). Organizations devoted to the promotion of 
evidence-based health care have emerged in the United States 
and internationally, seeking to increase the production of system-
atic reviews and evidence synthesization (Malekinejad, Horvath, 
Snyder, & Brindis, 2018). The World Health Organization has 
long acknowledged the importance of evidence in health through 
an advisory committee dedicated to health research and set up a 
sub-committee specifically to examine the use of research evi-
dence (Whitworth, 2006). While evidenced-based policy may be 
a positive goal to aim for, seeking complete evidence integration 
into government policy may be seen as naïve and potentially unob-
tainable (Cairney, 2016). It is more reasonable to expect that policy 
could be informed by evidence than based on it, as feasibility, equity 
and politics will routinely be factored into decision-maker process 
(Whitworth, 2006).
Governmental policies do not always clearly describe the evi-
dence that was used in their development or outline the process that 
was taken to incorporate evidence into the directions and guidelines 
(van de Goor et al., 2017). This study was a reverse of the traditional 
method of policy investigation, whereby the researchers looked at 
the policies to find the evidence supporting the use of a particular 
clinical practice, as opposed to looking at the evidence to ascertain 
whether it is followed. Because only two of the seven Australian ju-
risdictions received an evidence rating of A and those policies dif-
fered in their interpretation of the evidence that they did use, it is 
quite clear that there is more to be done in the promotion of re-
search into the use of PIVC for blood draws.
van de Goor et al. (2017) conducted a study of the reasons why 
European countries struggled to integrate evidence into their health 
policies. They found that having a lack of concrete evidence in spe-
cific areas, having a lack of existing evidence on the cost of specific 
procedures or programmes and lacking a joint and shared under-
standing of the barriers to implementation were significant reasons 
for reduced policy evidence uptake. More rigorous policy creation 
processes may be required to allow readers to understand the incon-
sistencies between policies, and the way evidence is used in policy 
creation and development (Oxman, Fretheim, Schünemann, & SURE, 
Fretheim & Schünemann, 2006).
It may seem intuitive to suggest that policymakers should make 
policy based on evidence; however, a strict application of evidence 
would remove the mandate of decision-making from those who 
were elected as the policymaker and decision-maker (Cairney, 2016). 
Healthcare decision-makers are often interested in using evidence 
to support their decision-making but may find that the scientific 
evidence available is inadequate for their needs (Tunis, Stryer, & 
Clancy, 2003). When making health policy decisions, decision-mak-
ers must navigate not just the scientific evidence, but also the intan-
gible and politically sensitive concepts of value judgement and public 
acceptability of actions (Mays, Pope, & Popay, 2005). Policymakers 
need evidence from a wide range of sources and often find that 
this evidence comes from personal contacts and individual expert 
sources (van de Goor et al., 2017).
Policymakers are also often required to create policies in areas 
where they are not experts and in situations where ambiguity 
around the scientific basis for specific actions exist (Cairney, 2016). 
Black and Donald (2001) provide an example of the different ways 
that government policies may interpret evidence, showing the con-
siderable variation in the international guidelines for cholesterol 
testing. These guidelines are based on identical evidence, and the 
variations can be attributed to differences in value judgements. 
Even among academic circles, there can be significant discrepancies 
in how complex scientific evidence is understood and interpreted 
(Black & Donald, 2001).
In the case of drawing blood from PIVCs, some government 
guidelines have set specific actions either prohibiting or encour-
aging blood draws. These stances are held despite a recent sys-
tematic review (Coventry et al., 2019) recommending that further 
research is required to inform the evidence for best practice rec-
ommendations to evaluate whether blood samples are similar if 
obtained by PIVC compared with venepuncture. The gaps in evi-
dence around the use of PIVCs may be a related to the lack of em-
phasis placed among research bodies on conducting clinical trials 
in a way that can meet the needs of decision-making bodies (Tunis 
et al., 2003).
A recent cross-sectional survey of nurses from across Australia 
failed to find a consensus between clinical professionals on whether 
taking blood from PIVC was acceptable practice, including within-state 
jurisdictions that have specified policies on PIVC blood taking (Davies 
et al., 2019). It is interesting to note that Black and Donald (2001) have 
suggested that increased involvement of clinical healthcare workers in 
policy creation may actually result in policies that contain lower levels 
of evidence. It may be that many senior nurses who have responsibility 
for policy development do not have the required academic skills to use 
the best available research. The implications for nurses and healthcare 
workers who are looking to improve the evidence base of the policies 
that they are working within are that may benefit from education and 
upskilling specifically related to understanding evidence and research 
capacity (Lee et al., 2020).
5.1 | Limitations
This paper looked at the evidence that was specifically cited in 
policies. There may have been additional evidence that was used 
to support the creation of policies, particularly expert opinions that 
may not have been referenced in the policies and thus could not be 
included.
5.2 | Recommendations
As current guidelines do not appear to use high levels of evidence, 
policymakers should give weight to the importance of academic 
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rigour in the creation of clinical policies and guidelines. State gov-
ernments should ensure that searches are conducted for academic 
evidence in support (or opposition) of specific practices prior to 
guideline publication. Policymakers may wish to consider providing 
grades of evidence to support specific policies, allowing for more 
open discussion over where new evidence is required.
Where there is clear evidence for a clinical policy, such as dwell 
time for PIVCs, decision-makers appear to be ignoring the evidence. 
State governments should consider employing people with aca-
demic skills and clinical experience in related professions in advisory 
roles prior to publication of health policy documents to review the 
evidence.
TA B L E  2   Types of evidence used
State Year Document Author(s)
Date for 
Review
References
Referenced in text
In text references 
specific for PIVC 
blood samplingTotal Academic Journals (Total)
Academic Journals (last  
5 years)a 
Legislation/ 
government policies/
guidelinesb 
Manufacturer 
guidelines Grey literaturec  Otherd 
ACT 2017 Health Directorate, Canberra 
Hospital and Health Services
2020 N = 15 N = 7 (47%) N = 2 (13%) N = 0 (0%) N = 2 (13%) N = 5 (33%) N = 1 (6%) No No
NSW 2013 Clinical Excellence Commission 2018 N = 15 N = 4 (27%) N = 0 (0%) N = 5 (33%) N = 0 (0%) N = 5 (33%) N = 1 (6%) No No
NT 2015 NT Clinical Guidelines Committee 2019 N = 12 N = 3 (25%) N = 1 (8%) N = 6 (50%) N = 0 (0%) N = 2 (17%) N = 1 (8%) No No
QLD 2015 Executive Director, Communicable 
Diseases Branch
June 2018 N = 119e  N = 58 (49%) N = 17 (14%) N = 7 (6%) N = 0 (0%) N = 34 (29%) N = 4 (3%) Yes Yes
N = 3
Tas 2016 Quality Management Committee 2019 N = 23 N = 9 (39%) N = 3 (13%) N = 1 (4%) N = 1 (4%) N = 7 (30%) N = 3 (13%) Yes Yes
N = 2
Vic 2012 Department of Human Services not stated N = 3f  N = 3 (100%) N = 0 (0%) N = 0 (0%) N = 0 (0%) N = 0 (0%) N = 0 (0%) No No
WA 2017 Communicable Disease Control 
Directorate
2021 N = 32 N = 14 (44%) N = 6 N = 13 N = 0 (0%) N = 4 N = 1 Yes Yes
N = 4
Abbreviations: ACT, Australian Capital Territory; and WA, Western Australia; NSW, New South Wales; NT, Northern Territory; QLD, Queensland;  
Tas, Tasmania; Vic, Victoria.
aThis study was conducted in 2018, so last 5yrs dates back to 2013. 
bLegislation was not cited exclusively by the states concerned with some policies including references to legislation from other state jurisdictions. 
cThis Grey Literature included material published by Non-governmental organizations and government documents below the level of legislation  
such as media statements 
d“Other” included books, websites (including some with links that were no longer valid at the time of extraction) and other sources that could not be  
classified in any of the specified categories. 
enote: the bibliography for this source stated 55 sources, but there was also an additional “reference list” with a further 66 sources. 2 were repeated,  
so there were a total of 119 references found. 
fThis document contained references after each chapter, the references stated here are those that were specifically placed after the chapter  
entitled Module 1: IV Cannulation. 
TA B L E  3   OCEBM*Level and type of evidence
State
Academic 
sources (N)
1 2 3 4 5
Grade of 
recommendationType of Evidence
Systematic 
review of 
RCT
RCT (- wide 
confidence 
interval)
All or 
none 
study
Systematic 
review of cohort 
studies
Individual cohort 
studies; low-quality 
RCT
Outcomes research;  
ecological studies'
Systematic review of 
case–control studies
Individual case–
control studies
Case 
series
Poor quality 
cohort studies
Poor quality case–
control studies
Expert opinion 
without critical 
appraisal
ACT 7 2 – – – 2 1 – – – – – 2 Grade B
NSW 4 – 4 – – – – – – – – – – Grade A
NT 3 2 – – – – – – – – – – 1 Grade B
QLD 58 9 6 – 8 9 – 1 2 4 1 22 Grade A
Tas 9 3 – – – 2 – – – – – – 4 Grade B
Vic 3 – – – – 1 – – – – – – 2 Grade D
WA 14 1 3 – – 2 1 – – – 1 – 6 Grade B
Note: Grade of Recommendation.
A: consistent level 1 studies.
B: consistent level 2 or 3 studies or extrapolations from level 1 studies.
C: level 4 studies or extrapolations from level 2 or 3 studies.
D: level 5 evidence or troubling inconsistent or inconclusive studies of any level.
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Involving clinicians and clinically trained academics in policy 
creation could assist with reducing the divide between policy and 
practice, as well as providing a conduit for communicating guidelines 
to clinical professionals. Future research could consider the capacity 
of clinical staff to engage with varying levels of evidence and the 
upskilling required to assist clinicians to think critically about knowl-
edge translation.
6  | CONCLUSION
The use of high-quality evidence in the creation of health policy is 
important to ensure that the policy results in positive health out-
comes. Health policy guidelines for the use of PIVC in blood sam-
pling in Australia are inconsistent and inconsistently supported by 
evidence. While it may not always be feasible for decision-makers 
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to base policies on evidence, they should be at the least informed 
by evidence. Barriers to evidence-based policy can include lack of 
available or consistent evidence and lack the skills of skills by de-
cision-makers to understand academic level clinical information. 
Governments should be at the forefront for using research-based 
evidence where available instead of informing themselves through 
the expert opinions and individual contacts.
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